Results 71 to 80 of about 51,890 (248)
Advanced Science, EarlyView.This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
HemaSphereThe 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma.
Anna deDaniel +10 more
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility [PDF]
, 2018 Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138 cell selection. A novel approach based on capillary nano-immunoassay could make it possible to quantify
Juan-José Lahuerta +27 more
core +1 more source
Next Questions: Multiple Myeloma
, 2021 The multiple myeloma field is moving forward quickly. In the past 12 months, many new insights have been generated through preclinical and clinical studies.
Landgren, C. Ola
core +1 more source
Genetic Code Expanded T Cell for Controllable Immunotherapy
Advanced Science, EarlyView.Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang +4 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Follicular lymphoma (FL) remains an incurable B‐cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating ...
Jinxing Zhang +10 more
wiley +1 more source
Advanced Science, EarlyView.A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng +5 more
wiley +1 more source
Journal of Hematology & OncologyBackground Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral replication in the cancer cells was ...
Ada Alice Dona +20 more
doaj +1 more source
New Treatment Approaches Multiple Myeloma
, 2018 The thesis is on current treatment approach to multiple Myeloma.Though an incurable disease as of now, great leaps have been taken in Myeloma management. This thesis focuses on different treatmet regimens used to treat different class of myeloma patients:
Issack, Sadam Mohamed
core